跳到正文
收录说明
收录范围
保留计量方法研究、相关统计基础,以及实质涉及计量方法的应用、教程、比较和综述。书评、刊务及明确无关内容不公开;身份或相关性证据不足的记录保留待核,补充可靠材料后可重新判断。
预印本来自 arXiv 计量经济学及相关统计、金融分类和主题检索。主题检索从 2021 年起回补;关注作者追溯更早年份,部分历史文献按已核验编号补录。收录不表示通过同行评审,仍可能遗漏。
本库首次提交范围:2004-06-23 — 2026-10-13。
阅读范围
默认显示本库全部预印本。可选“优先阅读”:至少一位作者同时满足有可核验的本站覆盖期刊正式发表记录,且 OpenAlex 总引用超过 1,000 次。按同一作者身份匹配,两项缺一不可。此筛选提供阅读线索,不作为论文质量判断。
日期与排序
默认按最近修订排序;年份和日期筛选使用首次提交时间。同一 arXiv 编号的修订会合并。仅有月份或年份时,日期区间相交也会纳入。

日期精度:到日 3 篇 · 到月 0 篇 · 到年 0 篇

分类与引用
领域和方法依据题名、摘要初步分类,可人工修正;分类不代表论文质量。引用数采用 OpenAlex 单条关联记录,不合计版本。
更新与 AI 解读
正常题录、可靠摘要与引用同步继续;日、周、月简报按核实的发表与修订日期汇总,历史补录保留在文献库。AI 解读依据可靠摘要或已核实原文片段,已有解读保留供阅读参考;缺少可靠材料的条目保持待解读,浏览页面不会触发生成。
3 篇论文
导出

Vaccine Efficacy Estimands Implied by Common Estimators Used in Individual Randomized Field Trials

个体随机实地试验中常用估计量隐含的疫苗效力目标量

We review vaccine efficacy (VE) estimands for susceptibility in individual randomized trials with natural (unmeasured) exposure, where individual responses are measured as time from vaccination until an event (e.g., disease from the infectious agent). Common VE estimands are written as $1-θ$, where $θ$ is some ratio effect measure (e.g., ratio of incidence rates, cumulative incidences, hazards, or odds) comparing outcomes under vaccination versus control. Although the ratio…

AI 解读阅读原文 ↗BibTeX ↓

Debiasing hazard-based, time-varying vaccine effects using vaccine-irrelevant infections: An observational extension of a pivotal Phase 3 COVID-19 vaccine efficacy trial

利用疫苗无关感染去偏随时间变化的风险率型疫苗效应

Understanding how vaccine effectiveness (VE) changes over time can provide evidence-based guidance for public health decision making. While commonly reported by practitioners, time-varying VE estimates obtained using Cox regression are vul- nerable to hidden biases. To address these limitations, we describe how to leverage vaccine-irrelevant infections to identify hazard-based, time-varying VE in the pres- ence of unmeasured confounding and selection bias. We articulate…

AI 解读阅读原文 ↗BibTeX ↓

A Surrogate Endpoint Based Provisional Approval Causal Roadmap

基于替代终点的临时批准因果路线图

For many rare diseases with no approved preventive interventions, promising interventions exist, yet it has been difficult to conduct a pivotal phase 3 trial that could provide direct evidence demonstrating a beneficial effect on the target disease outcome. When a promising putative surrogate endpoint(s) for the target outcome is available, surrogate-based provisional approval of an intervention may be pursued. We apply the Causal Roadmap rubric to define a surrogate…

AI 解读阅读原文 ↗BibTeX ↓